A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 04 2022
Historique:
received: 12 10 2021
accepted: 24 03 2022
entrez: 29 4 2022
pubmed: 30 4 2022
medline: 4 5 2022
Statut: epublish

Résumé

Hyperthermic intravesical chemotherapy (HIVEC)-whereby the bladder is heated to ± 43 °C during a chemotherapy instillation-can improve outcomes of non-muscle invasive bladder cancer (NMIBC) treatments. Experiments in animal models are required to explore new hyperthermia based treatments. Existing HIVEC devices are not suitable for rodents or large-scale animal trials. We present a HIVEC setup compatible with orthotopic rat models. An externally heated chemotherapeutic solution is circulated in the bladder through a double-lumen catheter with flow rates controlled using a peristaltic pump. Temperature sensors in the inflow channel, bladder and outflow channel allow temperature monitoring and adjustments in real-time. At a constant flow rate of 2.5 mL/min the system rapidly reaches the desired bladder temperature of 42-43 °C with minimal variability throughout a one-hour treatment in a rat bladder phantom, as well as in euthanised and live rats. Mean intraluminal bladder temperatures were 42.92 °C (SD = 0.15 °C), 42.45 °C (SD = 0.37 °C) and 42.52 °C (SD = 0.09 °C) in the bladder phantom, euthanised, and live rats respectively. Thermal camera measurements showed homogenous heat distributions over the bladder wall. The setup provides well-controlled thermal dose and the upscaling needed for performing large scale HIVEC experiments in rats.

Identifiants

pubmed: 35488115
doi: 10.1038/s41598-022-11016-y
pii: 10.1038/s41598-022-11016-y
pmc: PMC9054747
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7017

Informations de copyright

© 2022. The Author(s).

Références

Cancer Res. 1986 Dec;46(12 Pt 1):6242-5
pubmed: 3779644
J Urol. 2010 Sep;184(3):990-4; quiz 1235
pubmed: 20643429
Cancer Lett. 1997 Oct 28;119(1):47-52
pubmed: 18372521
Int J Hyperthermia. 2020;37(1):854-860
pubmed: 32664768
Cell Tissue Res. 1990 Oct;262(1):67-79
pubmed: 2257617
Int J Hyperthermia. 2017 Nov;33(7):733-740
pubmed: 28540814
Cancers (Basel). 2021 Mar 12;13(6):
pubmed: 33808973
World J Urol. 2011 Feb;29(1):73-7
pubmed: 21132553
J Urol. 2005 Apr;173(4):1375-80
pubmed: 15758808
Lasers Med Sci. 2013 Jul;28(4):1143-50
pubmed: 23053245
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Mol Cell. 2010 Oct 22;40(2):253-66
pubmed: 20965420
Front Oncol. 2020 Feb 05;10:29
pubmed: 32117709
Molecules. 2020 Jul 17;25(14):
pubmed: 32709143
BMC Urol. 2019 Dec 3;19(1):126
pubmed: 31795980
Acta Cir Bras. 2011;26 Suppl 2:106-10
pubmed: 22030824
Int J Hyperthermia. 2016 Jun;32(4):407-16
pubmed: 26939993
Int J Hyperthermia. 2003 Jan-Feb;19(1):45-57
pubmed: 12519711
Cancers (Basel). 2021 Jan 20;13(3):
pubmed: 33498535
Int J Hyperthermia. 2019;36(1):1147-1159
pubmed: 31752562
Bladder Cancer. 2017 Jul 27;3(3):201-210
pubmed: 28824948
Surg Oncol. 2016 Sep;25(3):281-97
pubmed: 27566035
Bladder Cancer. 2018 Oct 29;4(4):395-401
pubmed: 30417050
Cancers (Basel). 2021 Sep 15;13(18):
pubmed: 34572855
World J Urol. 2009 Jun;27(3):313-7
pubmed: 19219611
J Inorg Biochem. 2008 Apr;102(4):629-35
pubmed: 18037490
Int J Hyperthermia. 2014 May;30(3):166-70
pubmed: 24697672
Int J Nanomedicine. 2017 Apr 06;12:2793-2811
pubmed: 28435259
Radiat Oncol. 2015 Aug 07;10:165
pubmed: 26245485
Int J Hyperthermia. 2018;35(1):441-449
pubmed: 30303415
Int Urol Nephrol. 2016 Jan;48(1):79-84
pubmed: 26498630
Eur Urol. 2021 Apr;79(4):480-488
pubmed: 33419683
Int J Hyperthermia. 2016 Jun;32(4):434-45
pubmed: 27098923
Int J Hyperthermia. 2013 Dec;29(8):835-44
pubmed: 24050253
Mol Imaging. 2006 Jul;5(3):175-9
pubmed: 16954032
J Urol. 2015 Nov;194(5):1202-8
pubmed: 26143111
Cancer Chemother Pharmacol. 2014 Mar;73(3):503-9
pubmed: 24442034
Cancer Res. 1983 Jul;43(7):3231-5
pubmed: 6406056
Int J Nanomedicine. 2021 Jan 07;16:75-88
pubmed: 33447028
Eur Urol. 2016 Jun;69(6):1046-52
pubmed: 26803476
Adv Drug Deliv Rev. 2020;163-164:145-156
pubmed: 32247801
Proc SPIE Int Soc Opt Eng. 2013 Feb 26;8584:1656985
pubmed: 23837123
Eur Urol Oncol. 2019 May;2(3):239-247
pubmed: 31200837
Int J Hyperthermia. 2012;28(5):456-65
pubmed: 22690856
J Urol. 1990 Aug;144(2 Pt 1):370-4
pubmed: 2374209
Eur Urol. 2004 Nov;46(5):670-4
pubmed: 15474281
Int J Exp Pathol. 2003 Jun;84(3):145-52
pubmed: 12974944
Cells. 2020 Jul 25;9(8):
pubmed: 32722384

Auteurs

J W Van Hattum (JW)

Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands.

E M Scutigliani (EM)

Department of Medical Biology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands.

R F C P A Helderman (RFCPA)

Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands.
Department of Radiation Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands.

R Zweije (R)

Department of Radiation Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands.

H M Rodermond (HM)

Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands.

A L Oei (AL)

Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands.
Department of Radiation Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands.

J Crezee (J)

Department of Radiation Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands.

J R Oddens (JR)

Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands.

T M De Reijke (TM)

Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands.

P M Krawczyk (PM)

Department of Medical Biology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands. p.krawczyk@amsterdamumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH